Screening of household contacts for TB infection in Cote d'Ivoire.

SETTING: Côte d'Ivoire is a country with a high incidence of TB. The control of TB infection is focused on high-risk patients but has limited implementation. OBJECTIVE: Cost-benefit analysis of TB infection (TBI) screening of household contacts in Côte d'Ivoire to evaluate economic implications of the implementation of interferon-gamma release assays (IGRAs) and the tuberculin skin test (TST). DESIGN: We compared the effectiveness of QuantiFERON-TB Gold Plus (QuantiFERON) with the TST using an economic model previously evaluated in medium TB incidence settings. Principal outcomes relating to TBI screening, as well as the lifetime costs and benefits of the patient cohort, were captured using a decision tree, followed by a Markov model. RESULTS: QuantiFERON proved to be both more effective and less costly than TST. Compared to QuantiFERON, TST use leads to an approximate 33% increase in the lifetime risk of developing active TB. CONCLUSIONS: For household contacts of active TB cases in Côte d'Ivoire, QuantiFERON is cost-effective when compared with TST. R shiny interactive interface enables model customisation for different scenarios, settings, risk groups and TBI screening methods. Further research should be conducted in similar settings to generalise the results.

CONTEXTE: La Côte d'Ivoire est un pays où l'incidence de la TB est élevée. La lutte contre l'infection à TB est axée sur les patients à haut risque, mais sa mise en œuvre est limitée. OBJECTIF: Analyse coût-bénéfice du dépistage de l'infection à TB (TBI) chez les contacts familiaux en Côte d'Ivoire afin d'évaluer les implications économiques de la mise en œuvre des tests de libération de l'interféron-gamma (IGRA) et du test cutané à la tuberculine (TST). DESIGN: Nous avons comparé l'efficacité de QuantiFERON-TB Gold Plus (QuantiFERON) avec celle du TST en utilisant un modèle économique précédemment évalué dans des contextes d'incidence moyenne de la TB. Les principaux résultats relatifs au dépistage de la TBI, ainsi que les coûts et bénéfices à vie de la cohorte de patients, ont été saisis à l'aide d'un arbre de décision, suivi d'un modèle de Markov. RÉSULTATS: QuantiFERON s'est avéré à la fois plus efficace et moins coûteux que le TST. Par rapport à QuantiFERON, l'utilisation du TST entraîne une augmentation d'environ 33% du risque de développer une TB active au cours de la vie. CONCLUSIONS: Pour les contacts familiaux des cas de TB active en Côte d'Ivoire, QuantiFERON est rentable par rapport au TST. L'interface interactive R shiny permet de personnaliser le modèle pour différents scénarios, contextes, groupes à risque et méthodes de dépistage de la TBI. D'autres recherches devraient être menées dans des contextes similaires pour généraliser les résultats.

[Dynamic of indicators of ambulatory care of tuberculosis in the antituberculous center of Adjamé]. / Dynamique des indicateurs de la prise en charge ambulatoire de la tuberculose au centre antituberculeux d'Adjamé.

INTRODUCTION: Tuberculosis (TB) remains a real problem of public health in Côte d'Ivoire. The aim of our study is to describe the dynamic of anti-TB fight indicators in anti-TB center (CAT) of Adjamé. METHODOLOGY: We realized a retrospective study, comparing the anti-TB activities of two periods (1999-2001 versus 2010-2012) at the CAT of Adjamé. Over two periods, 24,520 cases of TB were recorded in the registers of TB declaration. RESULTS: Logistic regression results were the following ones. The proportion of the patients of Adjamé municipality increased to detriment of the patients coming from other municipalities. Our study showed an increase of TB contagious forms, a reduction of new cases of TB. The rate of screening of HIV infection increased. We noted a reduction of TB-HIV co-infection prevalence. The proportion of smear positive at the 2nd month decreased. We noted an increase of the rate therapeutic success and a reduction of lost at follow-up. CONCLUSION: Important progresses were realized in the TB fight and TB-HIV co-infection.

Erratum.

[This corrects the article on p. 166 in vol. 4, PMID: 25215193.].

Assessment of the genotype MTBDRplus assay for rifampin and isoniazid resistance detection on sputum samples in Cote d'Ivoire.

We conducted an evaluation study on the GenoType MTBDRplus assay's ability to detect mutations conferring resistance to rifampin and isoniazid directly from sputum taken from 120 smear positive pulmonary patients from tuberculosis (TB) centers in Cote d'Ivoire. The sputum was decontaminated by N-acetyl-l-cysteine (NALC) and comparatively analyzed with the MTBDRplus assay version 2.0 and the mycobacterial growth indicator tube (MGIT) 960 automated drug susceptibility testing (MGIT-DST). The Gene-Xpert Mycobacterium tuberculosis (MTB)/rifampicin (RIF) assay was performed for 21 sputa with absence of hybridization for at least one rpoB wild-type probes. Four and seven, respectively, discordant and concordant results were also analyzed. The mutations in the rpoB gene were 21 (17.5%), 20 (16.7%), 7 (5.8%), and 10 (8.3%), respectively, for D516V, H526Y, H526D, and S531L. S315T mutation in katG gene associated or not with mutation in promoter of inhA was detected in 76 (63.3%) of the sputum. Compared to MGIT-DST, the sensitivity and specificity of the MTBDRplus for rifampin resistance detection were 100% (75-100%) and 73.2% (61.3-84%), respectively. For isoniazid resistance detection, the sensitivity and specificity were, respectively, 95% (90-|99) and 95.1% (88.5-100%). Interpretation of 16 sputa without hybridization of rpoB wild-type probe 8 compared to those obtained with MGIT-DST and GeneXpert MTB/RIF was discordant and concordant, respectively, for 11 and 5.

Use of rapid molecular test for multidrug-resistant tuberculosis detection among relapse cases in Cote d'Ivoire.

UNLABELLED: Tuberculosis is explicitly recognized as a major global public health problem. In Côte d'Ivoire, relapse cases represent 66.5% of patients eligible for retreatment according to the National Tuberculosis Control Program. This study objective was to detect multidrug-resistance tuberculosis among relapse cases. Patients were recruited in tuberculosis centers in routine. A standardized questioning was administrated. Two sputum samples were collected and transported at Institut Pasteur. Sputum samples were decontaminated by NALC method. The DNA extraction was realized with 500µl of decontaminated sputum sample with smear-positive. MTBDRplus assay version 2.0 was performed according to the manufacturer's instruction. An internal quality control program with positive and negative controls was implemented for interpretation of results. In total 146 relapse cases with smear positive were studied. Out of selected patients, 130 had received the 2RHZE/4RH regimen and 16, the 2RHZES/1RHZE/5HRE. In group of relapse cases previously treated with 2RHZE/4RH regimen, 40 (31.3%, IC95%: [0.23; 0.39]) had punctual mutations at codon 526 in rpoB gene. Although, in patients under treated with 2RHZES/1RHZE/5HRE, a mutation in rpoB gene was identified in 12 of 16 sputum samples. Thirteen mutations conferring a resistance to Isoniazid were observed of which 9 in katG gene and 4 in katG and promoter region of inhA gene. The comparison (Chi-square with Yates correction) of resistance rates to Rifampin estimated showed a statistically significant difference. CONCLUSION: Use of a rapid method to detect drug-resistance in recurrent TB cases has permitted to identify patients eligible for first-line drugs or not.

[Multi-drug resistance of tuberculosis: 81 patients monitored in an Ivory Coast pneumology unit]. / Tuberculose multirésistante: à propos de 81 patients suivis dans un service de pneumologie en Côte d'Ivoire.

BACKGROUND: The Ivory Coast management of chronic tuberculosis (TB) began in 2000. OBJECTIVES: The aim of this study is to determine the characteristics of the patients monitored for chronic TB and note the difficulties in patient management and outcome. METHOD: A retrospective review of the medical records of the patients receiving second-line treatment for chronic tuberculosis for at least 12 months. RESULTS: Eighty-one medical records were included. The average of age was 33.37 years. The sex ratio was 2.68. All of the patients lived in conditions of promiscuity. The recommendations for the treatment of failures and relapses were not always respected: 33.33% did not comply with the protocols, 53.1% non-prescription of the mycobiogramme and 22.2% non-respect for the follow-up calendar. During the diagnosis of the chronic tuberculosis, bilateral radiological lesions were found in 72.5% of the cases and one lung was destroyed in 14.7% of the cases. The isolates were Mycobacterium tuberculosis. The multi-drug-resistance of Mycobacterium tuberculosis was estimated at 95.5%. The side effects of the treatments were polymorphous with a frequency ranging from 46.4% to 61.3% during the follow-up period. The outcome of the patients is the following: 39.2% dropped out; 15.2% died; 30.4% were in the attack phase; 5.1% were cured; 5.1% were in the consolidation phase. CONCLUSION: The results of the treatment are disappointing. It is urgent to develop a strategy to reduce the number of drop-outs and provide the early diagnosis and treatment of multi-drug resistant tuberculosis.

Evaluation de la prise en charge des pneumopathies interstitielles dans le service de PPH du CHU de Cocody du 1er Mars 2001 au 31 Aout 2003 : à propos de 72 cas colliges

Durant Ira periode du 1' mars 2001 au 31 aout 2003 nous avons effectue une etude retrospective dans 4 service de PPh du CHU de COCODY en vue d'evaluer la mise en oeuvre des recommandation etablies dans une premiere etude sur le meme sujet en 2001. Ainsi dans ta conduite de notre etude il nous fallait atteindre un objectif principal qui etait d'ameliorer la prise en charge des pneumopathies interstitielles devant aboutir e des objectifs specifiques qui sont: *Definir le profil clinique et radiologique des patients ayant une atteinte lnterstitielle ; *Determiner l'incidence du VIH/SIDA sur l'evoluton de ces atteintes ; *Determiner l'incidence des traitements sur revolution de ces atteintes ; *Definir les facteurs de mortalite des pneumopathies interstitielles ; Etablir un protocole therapeutique pour ta prise en charge de ces atteintes. Cette etude a porter sur 1428 dossiers dont 12 ont ete retenus sur l'analyse radiographique avec une predominance du sexe feminin surtout dans les franches d'Age de 21 a 40 ans et nec une duree d'hospitalisation en moyenne de 15 jours. Les motifs principaux de consultation etaient la dyspnee avec ou alteration de l'etat general avec ou une toux. Nous avons obtenu 1;38pour cent de serologie VIH+.; une anemie constante; sur le plan radiologique l'atteinte alveolo interstitielles predomine dans 93;44pour cent; la pneumopathie alveolo interstitielles non tuberculeuse s ete suspectee dans 59;72pour cent. 0e notre etude il ressort un taux eleve de mortalite de cette pathologie e hauteur 38;88pour cent des patients repertories surtout chez les patients traites essentiellement avec le cotrimoxazole avec 32;14pour cent des deces